• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Tris Pharma, Perigon Pharmacy Partner to Enhance ADHD Treatment Access


Joint venture aims to seamlessly deliver Dyanavel through Perigon’s digital pharmacy.

Businessman holding medical icon for health insurance concept in hospital background. Image Credit: Adobe Stock Images/Thanadon88

Image Credit: Adobe Stock Images/Thanadon88

Tris Pharma, Inc., a biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction, and neurological disorders, and Perigon Pharmacy 360, a specialty digital pharmacy, revealed plans to collaborate to enhance accessibility, affordability, and adherence for patients treating symptoms of ADHD with Tris’ Dyanavel (amphetamine) extended-release tablets. Through their partnership, the companies have launched Dyanavel Delivered, a direct-to-patient program that reportedly allows patients and caregivers to seamlessly access the medication through Perigon’s digital pharmacy, enhance their medication management, and receive reimbursement assistance.

“This partnership underscores our continued commitment to ensuring patients have access to the medications they need to treat their ADHD symptoms,” said Ketan Mehta, founder, CEO, Tris Pharma. “In an environment where shortages have been significant and widespread for more than a year, Tris Pharma is among the relatively few companies that have managed to not only maintain but increase supply of our ADHD medications without interruption. Our program with Perigon builds on this success by offering patients a more convenient way to consistently obtain access to their Dyanavel XR extended-release tablet prescription.”

Reference: Tris Pharma Partners with Perigon Pharmacy 360 to Enhance Access to DYANAVEL XR Tablets for the Treatment of Attention Deficit Hyperactivity Disorder. BusinessWire. October 30, 2023. Accessed October 30, 2023. https://www.businesswire.com/news/home/20231030473270/en/Tris-Pharma-Partners-with-Perigon-Pharmacy-360-to-Enhance-Access-to-DYANAVEL%C2%AE-XR-Tablets-for-the-Treatment-of-Attention-Deficit-Hyperactivity-Disorder

Recent Videos
Related Content